• 1. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 2. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 5. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Halobenzenes Iodobenzenes

Research Briefing on 3-Bromo-5-iodotoluene (CAS: 116632-38-3) in Chemical Biology and Pharmaceutical Applications

3-Bromo-5-iodotoluene (CAS: 116632-38-3) is a halogenated aromatic compound that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound serves as a critical intermediate in the synthesis of complex organic molecules, particularly in the development of novel therapeutic agents and diagnostic tools. The unique reactivity of its bromo and iodo substituents makes it a valuable building block for cross-coupling reactions, which are pivotal in modern medicinal chemistry.

Recent studies have highlighted the role of 3-Bromo-5-iodotoluene in the synthesis of targeted small-molecule inhibitors. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the construction of potent kinase inhibitors, which are being explored for cancer therapy. The compound's ability to undergo selective functionalization at either the bromo or iodo position allows for the generation of diverse molecular scaffolds, enabling researchers to fine-tune the pharmacological properties of the resulting compounds.

In addition to its synthetic applications, 3-Bromo-5-iodotoluene has been investigated for its potential in radiopharmaceuticals. A recent preprint on bioRxiv detailed its use as a precursor for the radiolabeling of imaging agents, which are essential for positron emission tomography (PET) scans. The iodo substituent, in particular, can be replaced with radioactive isotopes such as iodine-124, providing a pathway for the development of next-generation diagnostic tools.

From a mechanistic perspective, the reactivity of 3-Bromo-5-iodotoluene has been elucidated through advanced computational and experimental techniques. Density functional theory (DFT) calculations have revealed the electronic effects of the substituents on the toluene ring, which influence the compound's participation in palladium-catalyzed cross-coupling reactions. These insights are crucial for optimizing reaction conditions and improving yields in large-scale pharmaceutical production.

Despite its promising applications, challenges remain in the handling and storage of 3-Bromo-5-iodotoluene due to its sensitivity to light and moisture. Recent advancements in stabilization techniques, such as the use of inert atmospheres and specialized packaging, have addressed some of these issues, ensuring the compound's reliability in industrial and research settings.

Looking ahead, the continued exploration of 3-Bromo-5-iodotoluene is expected to yield further breakthroughs in drug discovery and chemical biology. Its adaptability in diverse synthetic routes and its role in cutting-edge diagnostic technologies underscore its importance in the field. Future research directions may include the development of greener synthetic protocols and the expansion of its applications in personalized medicine.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)